3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
175
HER2-positive Breast Cancer
16
Neoplasms
11
Neoplasm Metastasis
10
Prostatic Neoplasms
7
Ovarian Neoplasms
7
Stomach Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Pancreatic Neoplasms
5
Inflammatory Breast Neoplasms
5
Colonic Neoplasms
5
Brain Neoplasms
5
Triple Negative Breast Neoplasms
4
Multiple Myeloma
4
Hematologic Neoplasms
4
Endometrial Neoplasms
4
Colorectal Neoplasms
4
Urinary Bladder Neoplasms
3
Solid Tumor
3
Rectal Neoplasms
3
Pathologic Complete Response
3
Lymphoma, Non-Hodgkin
3
Lung Neoplasms
3
HER2-positive Early Breast Cancer
3
Esophageal Neoplasms
3
Breast Neoplasms, Male
3
Biliary Tract Neoplasms
3
Anatomic Stage I Breast Cancer AJCC v8
3
Salivary Gland Neoplasms
2
Locally Advanced Breast Cancer
2
Interventions
Blood Specimen Collection
9
Liquid Biopsy
4
cabazitaxel
3
Trastuzumab
3
Surgical Procedures, Operative
3
Propofol
3
Bevacizumab
3
Standard of Care
2
Spinal Puncture
2
Sevoflurane
2
Positron Emission Tomography Computed Tomography
2
Pirinitramide
2
Morphine
2
Laparoscopy
2
Folfox protocol
2
Epirubicin
2
Drug Therapy
2
Cyclophosphamide
2
Cetuximab
2
Carboplatin
2
Aspirin
2
Anesthesia, General
2
ribociclib
1
pertuzumab
1
osimertinib
1
jinfukang
1
eribulin
1
Zoledronic Acid
1
Vinorelbine
1
Thiotepa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplastic Cells, Circulating
×
pertuzumab
×
Clear all
NCT04993014
2021-08-06
HER2Cell
AC Camargo Cancer Center
Phase 2
Recruiting
80 enrolled